Articles

Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden

Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE), Bordeaux, France; Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Department of Pediatrics, Sainte-Justine University Hospital, Université de Montréal, Montréal, Québec
Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE), Bordeaux, France; Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC (CICP), Centre d’Investigation Clinique (CIC) 1401, INSERM Bordeaux
Pediatric Hematology Unit, Robert Debré University Hospital, AP-HP, Paris
Department of Pediatric Hematology, La Timone Hospital, Marseille University Hospital, Marseille
Department of Pediatric Hematology, La Timone Hospital, Marseille University Hospital, Marseille
Institute of Pediatric Hematology and Oncology, Lyon University Hospital, Lyon
Pediatric Immuno-Hematology and Rheumatology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris, France; Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France; Imagine Institute, UMR 1163 INSERM and Paris University, Paris
Department of Pediatric Hematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille
Pediatric Oncology Immunology Hematology Unit, Children’s University Hospital, Toulouse
Department of Pediatrics, Bicêtre University Hospital, AP-HP, Le Kremlin-Bicêtre
Department of Pediatric Hematology and Oncology, Rouen University Hospital, Rouen
Pediatric Unit, Angers University Hospital, Angers
Pediatric Oncology Hematology Unit, Grenoble University Hospital, Grenoble
Department of Hemato-Oncology Pediatric, Nice University Hospital, Nice
Department of Pediatric Hematology-Oncology, Clocheville Hospital, Tours University Hospital, Tours
Pediatric Oncology Hematology Unit, Arnaud de Villeneuve University Hospital, Montpellier
Department of Pediatric Hematology, Poitiers University Hospital, Poitiers
Department of Pediatric Hematology and Oncology, Hautepierre University Hospital, Strasbourg
Pediatric Hematology Unit, Nantes University Hospital, Nantes
Department of Pediatric Hematology-Oncology, Besanc_on University Hospital, Besanc_on
Pediatric Hematology Unit, Rennes University Hospital, Rennes
Pediatric Hematology Unit, Nancy University Hospital, Nancy
Pediatric Oncology Hematology Unit, Limoges University Hospital, Limoges
Pediatric Oncology-Hematology Unit Department, Caen University Hospital, Caen
Department of Pediatrics, Dijon University Hospital, Dijon
Pediatric Unit, Clermont-Ferrand University Hospital, Clermont-Ferrand
Imagine Institute, UMR 1163 INSERM and Paris University, Paris, France; Study Center for Primary Immunodeficiencies, Necker-Enfants Malades University Hospital, AP-HP, Paris
Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France; Imagine Institute, UMR 1163 INSERM and Paris University, Paris
Pediatric Oncology Immunology Hematology Unit, Armand-Trousseau University Hospital, AP-HP, Paris
Pediatric Oncology Immunology Hematology Unit, Armand-Trousseau University Hospital, AP-HP, Paris
Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE), Bordeaux, France; Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC (CICP), Centre d’Investigation Clinique (CIC) 1401, INSERM Bordeaux
Haematologica Early view Jan 14, 2021 https://doi.org/10.3324/haematol.2020.271106